Abstract:Temporal aspects of ligand specificity have been shown to play a significant role in the case of pulsatile hormone secretion, as exemplified by parathyroid hormone (PTH) binding to its receptor (PTH1R), a G-protein-coupled receptor expressed on surfaces of osteoblasts and osteocytes. The latter binding reaction regulates intracellular signalling and subsequently modulates skeletal homeostasis via bone remodelling. PTH glandular secretion patterns dictate bone cellular activity. In healthy humans, 70% of PTH is secreted in a tonic fashion, whereas 30% is secreted in low-amplitude and high-frequency bursts occurring every 10–20 min, superimposed on the tonic secretion. Changes in the PTH secretion patterns have been associated with various bone diseases. In this paper, we analyse PTH glandular secretion patterns for healthy and pathological states and their link to bone cellular responsiveness ( α R ). We utilise a two-state receptor ligand binding model of PTH to PTH1R together with a cellular activity function which is able to distinguish various aspects of the stimulation signal including peak dose, time of ligand exposure, and exposure period. Formulating and solving several constrained optimisation problems, we investigate the potential of pharmacological manipulation of the diseased glandular secretion and via clinical approved external PTH injections to restore healthy bone cellular responsiveness. Based on the mean experimentally reported data, our simulation results indicate cellular responsiveness in healthy subjects is sensitive to the tonic baseline stimulus and it is 28% of the computed maximum responsiveness. Simulation results for pathological cases of glucocorticoid-induced osteoporosis, hyperparathyroidism, initial and steady state hypocalcemia clamp tests indicate α R values significantly larger than the healthy baseline (1.7, 2.2, 4.9 and 1.9-times, respectively). Manipulation of the pulsatile glandular secretion pattern, while keeping the mean PTH concentration constant, allowed restoration of healthy baseline values from these catabolic bone diseases. Conversely, PTH glandular diseases that led to maximum bone cellular responsiveness below the healthy baseline value can’t be restored to baseline via glandular manipulation. However, external PTH injections allowed restoration of these latter cases.

PTH induces modification of transductive events in otosclerotic bone cell cultures

PTH[1-34] Improves the Effects of Core Decompression in Early-Stage Steroid-Associated Osteonecrosis Model by Enhancing Bone Repair and Revascularization

Parathyroid hormone regulates osteoblast differentiation positively or negatively depending on the differentiation stages

Immunolocalization of Enzymes/Membrane Transporters Related to Bone Mineralization in the Metaphyses of the Long Bones of Parathyroid-Hormone-Administered Mice.

Effects of PTH glandular and external dosing patterns on bone cell activity using a two-state receptor model—Implications for bone disease progression and treatment

Longitudinal Effects of Parathyroid Hormone Treatment on Morphological, Densitometric and Mechanical Properties of Mouse Tibia

Intermittent PTH Administration Increases Bone-Specific Blood Vessels and Surrounding Stromal Cells in Murine Long Bones

Method of Parathyroid Hormone Acting on Bone Metabolism--related Genes Expression of Old Rats' Bone Marrow Cells

Role of Gap Junction, Hemichannels, and Connexin 43 in Mineralizing in Response to Intermittent and Continuous Application of Parathyroid Hormone.

ClC-3 Chloride Channel Mediates the Role of Parathyroid Hormone [1-34] on Osteogenic Differentiation of Osteoblasts.

[Physiopathology of otosclerosis. Preliminary research]

Histological functions of parathyroid hormone on bone formation and bone blood vessels

Immunohistochemical and Morphometric Assessment on the Biological Function and Vascular Endothelial Cells in the Initial Process of Cortical Porosity in Mice With PTH Administration

Parathyroid Hormone Increases Activating Transcription Factor 4 Expression and Activity in Osteoblasts: Requirement for Osteocalcin Gene Expression.

Mutual Up-Regulation of Thyroid Hormone and Parathyroid Hormone Receptors in Rat Osteoblastic Osteosarcoma 17/2.8 Cells1

Effects of parathyroid hormone on proliferation of rat osteoblasts and osteoprotegerin expression

PTH and the Regulation of Mesenchymal Cells within the Bone Marrow Niche

Effect of Parathyroid Hormone on the Structural, Densitometric and Failure Behaviors of Mouse Tibia in the Spatiotemporal Space.

Stimulation of RANKL and Inhibition of Membrane‐Type Matrix Metalloproteinase‐1 Expression by Parathyroid Hormone in Normal Human Osteoblasts

Effects of Parathyroid Hormone on Osteoprotegerin Expression and Osteoprotegerin Ligand and Their Related Cytokines in Human Osteoblasts

Combination of parathyroid hormone pretreatment and mechanical stretch promotes osteogenesis of periodontal ligament fibroblasts